Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Biosimilar PK Study in Healthy Volunteers
NCT05476341Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2017
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bevacizumab in rectal cancer, lung cancer, ovarian cancer and 2 more (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Plasma concentration-area under time curve (AUC0-t) at Day 71. Started Apr 2017; status: completed.
02
Drugs
bevacizumab
03
Conditions
rectal cancerlung cancerovarian cancerCervical Cancer (CC)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05476341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476341.